Hot Gold Stocks To Own Right Now

tags:EVA,HIFS,AGEN,ADI,SIFI,

One of the main ways hedge funds make money is betting against companies they believe are overvalued, so investors should be wary of stocks with high levels of so-called short interest.

Goldman Sachs listed which stocks professional managers are short selling the most in its latest "Hedge Fund Trend Monitor" report by Ben Snider on Friday.

The firm's very important short positions basket consists of 50 S&P 500 stocks with the "highest total dollar value of short interest outstanding."

show chapters The market’s ‘fear gauge’ may be signaling caution for stocks    20 Hours Ago | 01:19

Shorting is a trading strategy that involves selling borrowed shares with a view that the stock will drop in value and the shares can be bought back later and returned for a profit.

Hot Gold Stocks To Own Right Now: Enviva Partners, LP(EVA)

Advisors' Opinion:

• [By Stephan Byrd]

  Enviva Partners (NYSE:EVA) had its price objective trimmed by Royal Bank of Canada to $33.00 in a research note issued to investors on Monday. The firm currently has an outperform rating on the energy company’s stock.

• [By Tyler Crowe]

  Typically when a company experiences an "act of God" event like a fire or a flood, investors can shrug off the issue. This past quarter, though, a fire at one of Enviva Partners' (NYSE:EVA) export terminals exposed something incredibly important about the business and some of management's recent decisions.

Hot Gold Stocks To Own Right Now: Hingham Institution for Savings(HIFS)

Advisors' Opinion:

• [By Max Byerly]

  Port Capital LLC lifted its stake in Hingham Institution for Savings (NASDAQ:HIFS) by 14.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,159 shares of the savings and loans company’s stock after purchasing an additional 5,943 shares during the quarter. Hingham Institution for Savings accounts for approximately 1.4% of Port Capital LLC’s holdings, making the stock its 25th biggest position. Port Capital LLC owned approximately 2.28% of Hingham Institution for Savings worth $9,921,000 at the end of the most recent reporting period.

Hot Gold Stocks To Own Right Now: Agenus Inc.(AGEN)

Advisors' Opinion:

• [By Max Byerly]

  Agenus (NASDAQ:AGEN) shares traded up 5.6% during mid-day trading on Thursday . The stock traded as high as $3.44 and last traded at $3.60. 39,070 shares were traded during mid-day trading, a decline of 97% from the average session volume of 1,431,827 shares. The stock had previously closed at $3.41.

• [By Cory Renauer]

  Attention bargain shoppers: There could be some deals in aisle biotech.�Agenus Inc.�(NASDAQ:AGEN)�and�Regeneron Pharmaceuticals (NASDAQ:REGN) dished out some disappointing losses in recent months, but the market's reaction to recent events seems a bit overdone.��

• [By Shane Hupp]

  Shares of Agenus (NASDAQ:AGEN) dropped 9.8% during trading on Monday following a dissappointing earnings announcement. The stock traded as low as $3.30 and last traded at $3.32. Approximately 2,421,286 shares changed hands during mid-day trading, an increase of 53% from the average daily volume of 1,586,724 shares. The stock had previously closed at $3.68.

• [By Cory Renauer]

  Harnessing the power of the immune system to fight cancer is a big deal and Agenus Inc. (NASDAQ:AGEN) looks like a great way to follow the trend. This stock trades like a small-cap biotech, but a couple of candidates coming through its pipeline could help push annual revenue past the $1 billion mark. Plus, by this time next year, the company could have half a dozen or so new candidates in clinical trials.

Hot Gold Stocks To Own Right Now: Analog Devices, Inc.(ADI)

Advisors' Opinion:

• [By Stephan Byrd]

  Get a free copy of the Zacks research report on Analog Devices (ADI)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Ethan Ryder]

  Strategy Asset Managers LLC purchased a new position in Analog Devices (NASDAQ:ADI) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 30,582 shares of the semiconductor company’s stock, valued at approximately $2,787,000.

• [By Joseph Griffin]

  Conning Inc. trimmed its position in shares of Analog Devices (NASDAQ:ADI) by 14.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,867 shares of the semiconductor company’s stock after selling 1,925 shares during the period. Conning Inc.’s holdings in Analog Devices were worth $1,081,000 at the end of the most recent quarter.

• [By Stephan Byrd]

  Ardevora Asset Management LLP reduced its stake in shares of Analog Devices (NASDAQ:ADI) by 0.7% in the first quarter, HoldingsChannel reports. The institutional investor owned 346,931 shares of the semiconductor company’s stock after selling 2,369 shares during the period. Ardevora Asset Management LLP’s holdings in Analog Devices were worth $31,616,000 at the end of the most recent reporting period.

• [By Stephan Byrd]

  Analog Devices (NASDAQ:ADI) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Analog Devices is benefiting from strong industrial, automotive and communications end-markets. While Analog Devices’ investments are aimed at strengthening the product line and countering increasing competition, the policy of returning cash through dividends and share buybacks ensures investor loyalty. The company is currently riding on strength across all the markets and positive contributions from Linear Technology acquisition. Analog Devices' leading market position, focus on communications, automotive and industrial markets, margin expansion initiatives and strong balance sheet are positives.  Notably, the stock has outperformed the industry it belongs to over a year. However, we remain concerned about competitive pressure across several markets.”

• [By Joseph Griffin]

  Aditus (CURRENCY:ADI) traded 0.3% lower against the U.S. dollar during the 24 hour period ending at 14:00 PM E.T. on May 14th. In the last seven days, Aditus has traded 164.5% higher against the U.S. dollar. Aditus has a market cap of $9.93 million and approximately $1.63 million worth of Aditus was traded on exchanges in the last 24 hours. One Aditus token can now be purchased for $0.0424 or 0.00000485 BTC on exchanges including CoinBene, COSS and IDEX.

Hot Gold Stocks To Own Right Now: SI Financial Group Inc.(SIFI)

Advisors' Opinion:

• [By Logan Wallace]

  News articles about SI Financial Group (NASDAQ:SIFI) have been trending somewhat positive recently, Accern reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. SI Financial Group earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned news stories about the savings and loans company an impact score of 47.0536892575283 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Franklin Resources Inc. Has $397.28 Million Stake in DXC Technology (DXC)

Franklin Resources Inc. reduced its stake in DXC Technology (NYSE:DXC) by 42.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,951,847 shares of the company’s stock after selling 2,922,912 shares during the quarter. Franklin Resources Inc. owned about 1.38% of DXC Technology worth $397,283,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of DXC. Stuart Chaussee & Associates Inc. bought a new position in DXC Technology in the 4th quarter valued at approximately $100,000. Calton & Associates Inc. bought a new position in DXC Technology in the 4th quarter valued at approximately $112,000. Financial Gravity Companies Inc. bought a new position in DXC Technology in the 4th quarter valued at approximately $130,000. Signaturefd LLC bought a new position in DXC Technology in the 1st quarter valued at approximately $137,000. Finally, BB&T Investment Services Inc. bought a new position in DXC Technology in the 4th quarter valued at approximately $143,000. 83.99% of the stock is currently owned by hedge funds and other institutional investors.

Get DXC Technology alerts:

NYSE DXC opened at $94.21 on Friday. The firm has a market cap of $26.91 billion, a PE ratio of 11.85, a PEG ratio of 1.00 and a beta of 0.94. The company has a current ratio of 0.99, a quick ratio of 0.99 and a debt-to-equity ratio of 0.48. DXC Technology has a 1-year low of $73.51 and a 1-year high of $107.85.

DXC Technology (NYSE:DXC) last released its quarterly earnings results on Thursday, May 24th. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.06. The firm had revenue of $6.29 billion for the quarter, compared to analysts’ expectations of $6.12 billion. DXC Technology had a return on equity of 18.14% and a net margin of 7.13%. The firm’s revenue was up 233.2% compared to the same quarter last year. analysts forecast that DXC Technology will post 8.15 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 17th. Stockholders of record on Wednesday, June 6th will be issued a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 0.81%. This is a boost from DXC Technology’s previous quarterly dividend of $0.18. The ex-dividend date of this dividend is Tuesday, June 5th. DXC Technology’s dividend payout ratio is presently 9.07%.

Several equities analysts recently issued reports on the company. ValuEngine raised DXC Technology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 10th. Berenberg Bank assumed coverage on DXC Technology in a research report on Wednesday, April 18th. They issued a “hold” rating and a $100.00 price objective on the stock. BMO Capital Markets reaffirmed a “buy” rating on shares of DXC Technology in a research report on Friday, February 23rd. Citigroup upped their price objective on DXC Technology to $126.00 and gave the company a “top pick” rating in a research report on Thursday, April 12th. Finally, JPMorgan Chase & Co. upped their price objective on DXC Technology to $114.00 and gave the company an “overweight” rating in a research report on Thursday, April 5th. Seven investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $107.00.

In other news, insider John M. Lawrie sold 5,000 shares of the company’s stock in a transaction on Friday, April 27th. The stock was sold at an average price of $103.04, for a total value of $515,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider John M. Lawrie sold 9,900 shares of the company’s stock in a transaction on Wednesday, April 11th. The stock was sold at an average price of $102.35, for a total value of $1,013,265.00. Following the completion of the sale, the insider now owns 638,610 shares of the company’s stock, valued at $65,361,733.50. The disclosure for this sale can be found here. Insiders sold a total of 22,886 shares of company stock valued at $2,343,380 over the last 90 days. 1.30% of the stock is currently owned by company insiders.

DXC Technology Company Profile

DXC Technology Company, together with its subsidiaries, provides information technology services and solutions primarily in North America, Europe, Asia, and Australia. It operates through three segments: Global Business Services (GBS), Global Infrastructure Services (GIS), and United States Public Sector (USPS).

3 Reasons You Might Fail a Background Check at Work

You sailed through the interview process and landed a job offer. Great! But before you make plans to set up your new desk and meet your new coworkers, you'll need to get through one more hurdle: the background check.

Though the practice is more common in certain industries than others, an estimated 72% of employers run background checks on new employees before hiring them officially. And while you might think you've got nothing to hide as far as your history goes, here are a few reasons why you might fail a background check and lose your dream opportunity.

IMAGE SOURCE: GETTY IMAGES.

1. You have a criminal history

Maybe you were convicted of a crime years ago and have had a clean record since. Depending on the scenario at hand, that could cause a company to rescind its offer. That said, an employer might consider moving forward regardless depending on the nature of the crime and its relation to the business at hand.

So what can you do if you know you have a criminal past? Your best bet is to come clean about it. Most employers will ask whether you've been convicted of a crime on your job application, so it pays to be honest and ask for an opportunity to explain what went wrong. Attempt to cover it up, however, and you might lose out on the job.

2. You have a poor credit history

You'd think your credit score would be a personal matter having nothing to do with your job prospects. Unfortunately, this isn't always the case. In most states, employers are allowed to access your credit history, and if yours spots a potential red flag, it could withdraw its employment offer. This is likely to happen if the job in question is one where you'll be tasked with handling money. After all, if you can't be trusted to manage your own finances, how can you be expected to manage your company's?

That's why it pays to work on boosting your credit rating before applying to jobs. If you know your score isn't great, try paying down some outstanding debt as quickly as you can. This will reduce your credit utilization ratio, which is one of several key factors that go into calculating your score. You also should take a look at your credit report and make sure it's correct. An estimated 20% of credit reports contain errors, and if you spot one and fix it, you'll be less likely to lose out on a job opportunity because of it.

3. You lied about your education

Maybe you went to college for a few semesters and never quite finished your degree. Or maybe you skipped college altogether, but lied about it on your resume. Bad move. As part of your background check, employers will often seek to verify that your educational credentials are what you claim them to be. If a company that wants to hire you discovers that you don't, in fact, have that bachelor's degree, you might instantly have your offer pulled back.

The solution? Don't lie about your education. If you only attended three out of four years of college, say so. You never know when a company might be willing to work with you -- for example, hire you on the condition that you complete your degree within two years and allow you the flexibility to work classes into your schedule -- so be truthful with regard to your credentials and play up other skills on your resume instead.

As a job seeker, the last thing you want is to lose out on a great opportunity because of a background check. So don't let that happen. Know what red flags companies look for, and take steps to either address or come clean about them to avoid surprises on the employer side. It's a far better bet than doing nothing, crossing your fingers, and magically hoping for the best.

State of New Jersey Common Pension Fund D Buys 21,422 Shares of BBVA Banco Frances S.A. (BFR)

State of New Jersey Common Pension Fund D boosted its stake in shares of BBVA Banco Frances S.A. (NYSE:BFR) by 26.1% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 103,406 shares of the bank’s stock after buying an additional 21,422 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in BBVA Banco Frances were worth $2,359,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Deutsche Bank AG raised its holdings in BBVA Banco Frances by 25.0% during the 4th quarter. Deutsche Bank AG now owns 1,508,601 shares of the bank’s stock valued at $38,015,000 after buying an additional 301,965 shares during the period. Eaton Vance Management purchased a new stake in BBVA Banco Frances in the fourth quarter worth $545,000. INCA Investments LLC increased its stake in BBVA Banco Frances by 60.9% in the fourth quarter. INCA Investments LLC now owns 952,500 shares of the bank’s stock worth $24,003,000 after purchasing an additional 360,700 shares during the period. Standard Life Aberdeen plc increased its stake in BBVA Banco Frances by 68.1% in the fourth quarter. Standard Life Aberdeen plc now owns 3,484,129 shares of the bank’s stock worth $87,818,000 after purchasing an additional 1,411,171 shares during the period. Finally, Global X Management Co. LLC increased its stake in BBVA Banco Frances by 21.7% in the fourth quarter. Global X Management Co. LLC now owns 334,963 shares of the bank’s stock worth $8,441,000 after purchasing an additional 59,634 shares during the period. Institutional investors own 17.83% of the company’s stock.

Get BBVA Banco Frances alerts:

BFR stock opened at $16.33 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.20 and a quick ratio of 1.20. BBVA Banco Frances S.A. has a twelve month low of $14.55 and a twelve month high of $27.45.

The firm also recently announced an annual dividend, which was paid on Wednesday, May 16th. Shareholders of record on Tuesday, May 8th were paid a $0.209 dividend. This is a positive change from BBVA Banco Frances’s previous annual dividend of $0.17. The ex-dividend date of this dividend was Monday, May 7th. This represents a yield of 1.22%. BBVA Banco Frances’s dividend payout ratio (DPR) is presently 18.42%.

A number of research firms have weighed in on BFR. ValuEngine lowered BBVA Banco Frances from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Santander upgraded BBVA Banco Frances from a “hold” rating to a “buy” rating in a research note on Friday, May 11th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. BBVA Banco Frances currently has a consensus rating of “Hold” and a consensus target price of $26.50.

About BBVA Banco Frances

BBVA Banco Franc茅s SA, together with its subsidiaries, provides financial services to small and medium enterprises, and individual customers in Spain, Mexico, South America, the United States, and Eurasia. The company offers current, checking, and savings accounts, as well as demand and time deposits.

Want to see what other hedge funds are holding BFR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BBVA Banco Frances S.A. (NYSE:BFR).

Celgene: Still (Looks) Appealing

Celgene (CELG) has been on my watchlist for a while as its shares continue to lag despite the promise of a rich pipeline, high regard of the company among the scientific community, and the continued decline in the share price which has increased my interest in the name.

In January, I wondered if Juno Therapeutics could rejuvenate the pipeline of Celgene, yet this addition came at a sizeable cost of $9 billion, as I held a small long position at the time. I liked the strategy of smaller bolt-on deals in the past, but this large deal and recent operating struggles in the pipeline might suggest that management has become less disciplined in its dealmaking.

2018 - A Challenge So Far

As briefly discussed above, Celgene has acquired Juno Therapeutics earlier this year at a total value of nearly $10 billion. The company already took a 10% stake in Juno about three years ago, which is a comforting sign for investors as it is familiar with the business.

The deal is all about JCAR017, a promising cellular immunotherapy development, for which Celgene sees peak sales at $3 billion at some point beyond 2020. The technology behind this so-called CAR T and TCR therapeutics could be evaluated for treatment of other cancer indications as well.

After the announcement of this deal and the release of the full year results for 2017, Celgene's shares continued to slip. Halfway February, Celgene announced a $5 billion share repurchase program to take advantage of the lower price. Even this news, as well as the first quarter results, could not comfort investors either, despite the fact that it appears that the company is off to a good start this year.

First Quarter Results And Valuation Discussion

Earlier in May, the company released the first quarter results as revenue growth accelerated to 20%, with revenues coming in at $3.54 billion. The reliance on Revlimid was stable as sales of the multiple myeloma blockbuster drug were up by 19% to $2.23 billion. The myeloma franchise is much bigger, however, as Celgene's second best drug Pomalyst belongs to that franchise as well. Its sales rose by 24% to $453 million.

Fortunately, the company has some other indications as well as they are slowly reducing the reliance on multiple myeloma. Otezla is a treatment for patients with active psoriatic arthritis, and sales of this drug rose by 46% to $353 million. Abraxane, an injectable suspension for treatment of metastatic breast cancer, reported an 11% increase in sales to $262 million.

Other smaller drugs include a flattish $157 million revenue contribution by Vidaza. The remaining smaller drugs are all in decline, including Thalomid with $31 million in sales and Istodax with $19 million in sales. Of course, Celgene benefits from the FDA approval of Idhafa in the third quarter of last year. After sales came in at $7 million in their debuting quarter and rose to $13 million in the final quarter of 2017, the sequential pick-up to $14 million in quarterly sales in the first quarter of this year looks a bit soft.

All in all, the earnings number is quite a bit more complicated. The company reported net earnings (on a GAAP basis) of $846 million, vs. $932 million last year, as aggressive share repurchases limited the decline in reported earnings from $1.15 per share to $1.10 per share. The gap with adjusted earnings was very large by all means, with adjusted earnings coming in at $1.57 billion, or $2.05 per share.

The non-GAAP number excludes quite a few items which are really costly to investors and are structural in their nature as well. One key item is roughly $400 million in stock-based compensation expenses (pre-tax) which after taxes could easily work out to $300-350 million, being a real expense. Even if I kindly accept the adjustment made in relation to R&D and collaboration expenses being taken, adjusted earnings could fall from $1.57 billion to levels closer to $1.3 billion if I factor in the stock-based compensation expense. That results in earnings of $1.70 per share, as even this number excludes structural charges taken in relation to R&D charges.

Following the solid sales numbers, the company now sees full year sales around $14.8 billion, after it previously guided for $14.4-14.8 billion in sales, driven by relative strength across the board. The company hiked the full year adjusted earnings guidance from $8.70-8.90 per share to $8.95 per share ahead of the Juno deal. Factoring in that deal, adjusted earnings are seen around $8.45 per share after management already indicated before that this deal would dilute this year's earnings by half a dollar.

With shares trading at $78, the multiples look very low at 9 times, but there are some caveats. As mentioned above, the gap with the GAAP numbers is likely to be substantial as GAAP earnings are seen at $6.31 per share, as potential further charges might lower that number. Yet even as there is a big gap between both earnings metrics, GAAP multiples remain very reasonable at 12-13 times earnings.

Another concern among investors is the rapid "deterioration" in the finances after the company traditionally operated with a strong net cash position, but this changed following recent share repurchases and deal-making efforts. Cash holdings stand at $4.7 billion, with debt amounting to $20.3 billion, for a $15.6 billion net debt load. Based on adjusted earnings of around $8.50 per share, adjusted earnings are seen at $6.5 billion this year. Adding back roughly half a billion in interest and applying back a near 20% tax rate, I come with adjusted EBITDA of around $8.5 billion, for a 1.8 times leverage ratio.

While leverage is still very manageable, and the valuation metrics look outright crazy, given the sales growth, it is understandable why investors act with caution as the company is largely an MM franchise, with great reliance on Revlimid. On the bright side, despite some failures in the much discussed pipeline, this pipeline is actually still relatively decent, certainly after the recent addition with the Juno deal. That being said, the process of a promising development in the pipeline to becoming a blockbuster drug is always a challenge.

The big elephant in the room is generic option for Revlimid, of course, as generic producers are pushing to start producing the generic version of the drug and have the public on their side with the drug costing close to a quarter of a million each year. If generic competition arises or prices have to be lowered following public outcry, that would have a big impact on earnings and leverage, given the reliance on the drug. The only good news is that it appears that the market has priced in these cuts to some extent already at these levels.

What Now?

I have been constructive on Celgene at the start of the year, but that was only after shares traded just below the $100 mark. That means that I am down a hefty 20% on my initial investment, as I like to average down. Having bought just a fifth of a desired "full" position, I am not too worried about this, yet wonder how aggressive I should be with averaging down.

The reliance on Revlimid and emerging discussion on effective patent protection is a concern simply for the sheer fact that the company relies so heavily on the drug. This does not have to be a problem, yet setbacks in the pipeline have created a gap in which no significant contribution is expected in the near term from other drugs. This could potentially create a similar situation as faced by Gilead with its declining HCV business, in a process which has been very painful for patient investors attracted to a very appealing cash flow yield, which unfortunately kept declining. Unlike Gilead, Celgene has now taken on quite a bit of debt (while Gilead operates with a relative strong balance sheet), and Celgene has seen real kickbacks in the pipeline, resulting in actual candidates being shut down for real.

For now, I am doubling my position to still just 40% of my target positioning, as I do feel that prospects have changed for the negative over the past twelve months following pipeline setbacks, expensive deals, buybacks at elevated levels, while Revlimid is coming closer to seeing real competition. If such event would arise, the $19-20 billion revenue target for 2020 and $12.50 earnings per share number projected for that year are way too optimistic, as a big reset in this guidance could furthermore shake out a few nerved long-term bulls.

The reliance on Revlimid, questionable M&A action, and debt being incurred create real risk despite the low expectations, as this prevents me from buying these dips in a more aggressive way.

Please subscribe to Value In Corporate Events - Marketplace Checkout to obtain premium research on all the latest IPOs, M&A activity and other corporate events. Reviews of situations will be made upon request!

Disclosure: I am/we are long CELG.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Marathon Oil Corp (MRO) President and CEO Lee M Tillman Sold $8.7 million of Shares

President and CEO of Marathon Oil Corp (NYSE:MRO) Lee M Tillman sold 400,000 shares of MRO on 05/17/2018 at an average price of $21.65 a share. The total sale was $8.7 million.

Marathon Oil Corp is an exploration and production company. It focuses on producing crude oil and condensate, natural gas liquids and natural gas as well as bitumen from oil sands deposits. Marathon Oil Corp has a market cap of $18.27 billion; its shares were traded at around $21.41 with and P/S ratio of 3.78. The dividend yield of Marathon Oil Corp stocks is 0.92%.

CEO Recent Trades:

President and CEO Lee M Tillman sold 400,000 shares of MRO stock on 05/17/2018 at the average price of $21.65. The price of the stock has decreased by 1.11% since.

Directors and Officers Recent Trades:

See Remarks Patrick Wagner sold 53,333 shares of MRO stock on 05/16/2018 at the average price of $21.2. The price of the stock has increased by 0.99% since.Executive VP - Operations Thomas Mitchell Little sold 21,286 shares of MRO stock on 05/07/2018 at the average price of $19.89. The price of the stock has increased by 7.64% since.

For the complete insider trading history of MRO, click here

.